TRB-061 Phase 1a/1b Study Initiated for Atopic Dermatitis
TRex Bio, Inc. has initiated Phase 1a/1b study of TRB-061, a subcutaneously administered therapeutic candidate, to evaluate its safety, pharmacokinetics, and pharmacodynamics in healthy adults and patients with moderate-to-severe atopic dermatitis.